---
document_datetime: 2026-01-20 15:02:00
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/evrysdi.html
document_name: evrysdi.html
version: success
processing_time: 0.1469078
conversion_datetime: 2026-01-20 20:32:17.221034
docling_version:
  docling-serve: 1.10.0
  docling-jobkit: 1.8.1
  docling: 2.69.0
  docling-core: 2.60.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.3
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Search

- [Medicines](/en/medicines)
    - [Find medicine](/en/medicines)
    - [Therapeutic areas: latest updates](/en/medicines/therapeutic-areas-latest-updates)
    - [Download medicine data](/en/medicines/download-medicine-data)
    - [What we publish on medicines and when](/en/medicines/what-we-publish-medicines-when)
    - [Medicines under evaluation](/en/medicines/medicines-human-use-under-evaluation)
    - [National registers](/en/medicines/national-registers-authorised-medicines)
- [Human regulatory](/en/human-regulatory-overview)
    - [Overview](/en/human-regulatory-overview)
    - [Research and development](/en/human-regulatory-overview/research-development)
    - [Marketing authorisation](/en/human-regulatory-overview/marketing-authorisation)
    - [Post-authorisation](/en/human-regulatory-overview/post-authorisation)
    - [Medical devices](/en/human-regulatory-overview/medical-devices)
    - [Herbal products](/en/human-regulatory-overview/herbal-medicinal-products)
- [Veterinary regulatory](/en/veterinary-regulatory-overview)
    - [Overview](/en/veterinary-regulatory-overview)
    - [Research and development](/en/veterinary-regulatory-overview/research-development-veterinary-medicines)
    - [Marketing authorisation](/en/veterinary-regulatory-overview/marketing-authorisation-veterinary-medicines)
    - [Post-authorisation](/en/veterinary-regulatory-overview/post-authorisation-veterinary-medicines)
- [Committees](/en/committees)
    - [Overview](/en/committees)
    - [How the committees work](/en/committees/how-committees-work)
    - [CHMP](/en/committees/committee-medicinal-products-human-use-chmp)
    - [CVMP](/en/committees/committee-veterinary-medicinal-products-cvmp)
    - [PRAC](/en/committees/pharmacovigilance-risk-assessment-committee-prac)
    - [COMP](/en/committees/committee-orphan-medicinal-products-comp)
    - [HMPC](/en/committees/committee-herbal-medicinal-products-hmpc)
    - [CAT](/en/committees/committee-advanced-therapies-cat)
    - [PDCO](/en/committees/paediatric-committee-pdco)
    - [Working parties and other groups](/en/committees/working-parties-other-groups)
- [News &amp; events](/en/news-events)
    - [Overview](/en/news-events)
    - [News](/en/news)
    - [Events](/en/events/upcoming-events)
    - [What's new](/en/news-events/whats-new)
    - [Committee highlights](/en/news-events/committee-highlights)
    - [Publications](/en/news-and-events/publications)
    - [Press and social media](/en/news-events/press-social-media)
    - [Podcast: Inside EMA](/en/news-events/podcast-inside-ema)
    - [Open consultations](/en/news-events/open-consultations)
    - [RSS feeds](/en/news-events/rss-feeds)
- [Partners &amp; networks](/en/partners-networks)
    - [Overview](/en/partners-networks)
    - [Animal health practitioners](/en/partners-networks/animal-health-practitioners)
    - [One Health approach](/en/partners-networks/one-health-approach)
    - [Academia](/en/partners-networks/academia)
    - [EU partners](/en/partners-networks/eu-partners)
    - [International activities](/en/partners-networks/international-activities)
    - [Patients and consumers](/en/partners-networks/patients-consumers)
    - [Healthcare professionals](/en/partners-networks/healthcare-professionals)
    - [Pharmaceutical industry](/en/partners-networks/pharmaceutical-industry)
    - [Networks](/en/partners-networks/networks)
    - [Health technology assessment bodies](/en/partners-networks/health-technology-assessment-bodies)
- [About us](/en/about-us)
    - [Overview](/en/about-us)
    - [What we do](/en/about-us/what-we-do)
    - [Who we are](/en/about-us/who-we-are)
    - [How we work](/en/about-us/how-we-work)
    - [Fees](/en/about-us/fees-payable-european-medicines-agency)
    - [Support to SMEs](/en/about-us/support-smes)
    - [Annual reports and work programmes](/en/about-us/annual-reports-work-programmes)
    - [History of EMA](/en/about-us/history-ema)
    - [Careers](/en/about-us/careers)
    - [Procurement](/en/about-us/procurement-grants)
    - [Glossaries](/en/about-us/glossaries)
    - [About this website](/en/about-us/about-website)
    - [Data protection and privacy](/en/about-us/data-protection-privacy-ema)
    - [Contacts](/en/about-us/contacts-european-medicines-agency)

1. [Home](/en/homepage)
2. [Medicines](https://www.ema.europa.eu/en/medicines)
3. Evrysdi

# Evrysdi

[RSS](/en/individual-human-medicine.xml/67433)

##### Authorised

This medicine is authorised for use in the European Union

risdiplam Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Evrysdi](#news-on)
- [Product information - with tracked changes](#product-information-with-tracked-changes-82859)
- [More information on Evrysdi](#more-information-on-evrysdi-32625)
- [More information on Evrysdi](#related-medicines)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Evrysdi is a medicine used to treat patients with 5q spinal muscular atrophy (SMA), a genetic disease that causes weakness and wasting of the muscles including the lung muscles. It is intended for patients with SMA type 1, type 2 or type 3, or those who have up to 4 copies of a gene known as SMN2.

SMA is rare, and Evrysdi was designated an 'orphan medicine' (a medicine used in rare diseases) on 26 February 2019. Further information on the orphan designation can be found here: [ema.europa.eu/medicines/human/orphan-designations/eu3192145](/en/medicines/human/orphan-designations/eu-3-19-2145) .

Evrysdi contains the active substance risdiplam.

Expand section

Collapse section

## How is Evrysdi used?

Treatment with Evrysdi must be started by a doctor experienced in treating SMA. The medicine can only be obtained with a prescription.

Evrysdi is taken by mouth once a day after a meal, at around the same time each day. In patients who are not able to swallow, Evrysdi can be given via a tube through the nose or skin to the stomach.

For more information about using Evrysdi, see the package leaflet or contact your doctor or pharmacist.

## How does Evrysdi work?

Patients with SMA lack a protein called 'survival motor neuron' (SMN) protein, which is essential for motor neurons (nerve cells in the spinal cord that control muscle movement) to continue working normally. Two genes, *SMN1* and *SMN2,* are involved in the production of the SMN protein. Patients with SMA lack the *SMN1* gene but have one or more copies of the *SMN2* gene, which mostly produce a short SMN protein that does not work as well as the full-length protein.

The active substance in Evrysdi, risdiplam, is a small molecule that allows the *SMN2* gene to produce the full-length protein, which can work normally. This is expected to increase survival of motor neurons, thereby reducing current symptoms of the disease and slowing down its progression.

## What benefits of Evrysdi have been shown in studies?

Evrysdi was shown to be effective at improving motor function in 2 main studies in patients with SMA.

One study conducted in 41 infants aged 2 to 7 months with type 1 SMA (the most severe type) showed that 29% (12 out of 41) of infants were able to sit without support for more than 5 seconds after 12 months of treatment with Evrysdi. Past observations of infants with SMA found that they are never able to sit without support.

A second study in 180 patients with type 2 and type 3 SMA up to 25 years of age showed a slight improvement in motor function (as measured using a rating scale called MFM32) in patients treated with Evrysdi: there was a 1.6-point difference compared with placebo (a dummy treatment) on a 100-point scale after 12 months of treatment.

Data from an additional study involving 18 newborn infants up to 6 weeks of age at the start of treatment support the use of Evrysdi in infants diagnosed with SMA but not yet showing symptoms. Of the seven children who received Evrysdi for at least 12 months, six reached milestones (such as sitting without support) which could normally not be attained by untreated children with 2 copies of SMN2.

## What are the risks associated with Evrysdi?

For the full list of side effects and restrictions of Evrysdi, see the package leaflet.

The most common side effects with Evrysdi (which may affect more than 1 in 10 people) include fever, rash, diarrhoea and headache.

## Why is Evrysdi authorised in the EU?

The effects of Evrysdi on the development of motor function in patients with SMA type 1, 2 and 3 were considered relevant, particularly considering the severity of the disease. In children with type 1 SMA, the most severe form of the disease, Evrysdi allows infants to sit without support for more than 5 seconds after a year of treatment, which they would not be able to do without treatment.

Evrysdi is also beneficial in patients with a later onset of SMA (type 2 and 3), although the effects in these patients are modest. The side effects with Evrysdi are considered manageable. Therefore, the European Medicines Agency decided that Evrysdi's benefits are greater than its risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Evrysdi?

The company that markets Evrysdi will provide data from a long-term study on the effects of the medicine in patients with up to 4 copies of the *SMN2* gene compared with how the disease progresses in patients who have not been treated with Evrysdi.

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Evrysdi have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Evrysdi are continuously monitored. Side effects reported with Evrysdi are carefully evaluated and any necessary action taken to protect patients.

## Other information about Evrysdi

Evrysdi received a marketing authorisation valid throughout the EU on 26 March 2021.

This overview was last updated in 08-2023.

Evrysdi : EPAR - Medicine overview

English (EN) (111.9 KB - PDF)

**First published:** 04/05/2021

**Last updated:** 22/09/2023

[View](/en/documents/overview/evrysdi-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-584)

български (BG) (138.66 KB - PDF)

**First published:**

04/05/2021

**Last updated:**

22/09/2023

[View](/bg/documents/overview/evrysdi-epar-medicine-overview_bg.pdf)

español (ES) (112.37 KB - PDF)

**First published:**

04/05/2021

**Last updated:**

22/09/2023

[View](/es/documents/overview/evrysdi-epar-medicine-overview_es.pdf)

čeština (CS) (136.36 KB - PDF)

**First published:**

04/05/2021

**Last updated:**

22/09/2023

[View](/cs/documents/overview/evrysdi-epar-medicine-overview_cs.pdf)

dansk (DA) (113.07 KB - PDF)

**First published:**

04/05/2021

**Last updated:**

22/09/2023

[View](/da/documents/overview/evrysdi-epar-medicine-overview_da.pdf)

Deutsch (DE) (116.85 KB - PDF)

**First published:**

04/05/2021

**Last updated:**

22/09/2023

[View](/de/documents/overview/evrysdi-epar-medicine-overview_de.pdf)

eesti keel (ET) (112.13 KB - PDF)

**First published:**

04/05/2021

**Last updated:**

22/09/2023

[View](/et/documents/overview/evrysdi-epar-medicine-overview_et.pdf)

ελληνικά (EL) (139.9 KB - PDF)

**First published:**

04/05/2021

**Last updated:**

22/09/2023

[View](/el/documents/overview/evrysdi-epar-medicine-overview_el.pdf)

français (FR) (114.07 KB - PDF)

**First published:**

04/05/2021

**Last updated:**

22/09/2023

[View](/fr/documents/overview/evrysdi-epar-medicine-overview_fr.pdf)

hrvatski (HR) (135.62 KB - PDF)

**First published:**

04/05/2021

**Last updated:**

22/09/2023

[View](/hr/documents/overview/evrysdi-epar-medicine-overview_hr.pdf)

italiano (IT) (113.3 KB - PDF)

**First published:**

04/05/2021

**Last updated:**

22/09/2023

[View](/it/documents/overview/evrysdi-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (150.05 KB - PDF)

**First published:**

04/05/2021

**Last updated:**

22/09/2023

[View](/lv/documents/overview/evrysdi-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (134.4 KB - PDF)

**First published:**

04/05/2021

**Last updated:**

22/09/2023

[View](/lt/documents/overview/evrysdi-epar-medicine-overview_lt.pdf)

magyar (HU) (136.86 KB - PDF)

**First published:**

04/05/2021

**Last updated:**

22/09/2023

[View](/hu/documents/overview/evrysdi-epar-medicine-overview_hu.pdf)

Malti (MT) (137.9 KB - PDF)

**First published:**

04/05/2021

**Last updated:**

22/09/2023

[View](/mt/documents/overview/evrysdi-epar-medicine-overview_mt.pdf)

Nederlands (NL) (115.16 KB - PDF)

**First published:**

04/05/2021

**Last updated:**

22/09/2023

[View](/nl/documents/overview/evrysdi-epar-medicine-overview_nl.pdf)

polski (PL) (137.26 KB - PDF)

**First published:**

04/05/2021

**Last updated:**

22/09/2023

[View](/pl/documents/overview/evrysdi-epar-medicine-overview_pl.pdf)

português (PT) (114.71 KB - PDF)

**First published:**

04/05/2021

**Last updated:**

22/09/2023

[View](/pt/documents/overview/evrysdi-epar-medicine-overview_pt.pdf)

română (RO) (133.76 KB - PDF)

**First published:**

04/05/2021

**Last updated:**

22/09/2023

[View](/ro/documents/overview/evrysdi-epar-medicine-overview_ro.pdf)

slovenčina (SK) (136.08 KB - PDF)

**First published:**

04/05/2021

**Last updated:**

22/09/2023

[View](/sk/documents/overview/evrysdi-epar-medicine-overview_sk.pdf)

slovenščina (SL) (134.04 KB - PDF)

**First published:**

04/05/2021

**Last updated:**

22/09/2023

[View](/sl/documents/overview/evrysdi-epar-medicine-overview_sl.pdf)

Suomi (FI) (110.18 KB - PDF)

**First published:**

04/05/2021

**Last updated:**

22/09/2023

[View](/fi/documents/overview/evrysdi-epar-medicine-overview_fi.pdf)

svenska (SV) (111.6 KB - PDF)

**First published:**

04/05/2021

**Last updated:**

22/09/2023

[View](/sv/documents/overview/evrysdi-epar-medicine-overview_sv.pdf)

Evrysdi : EPAR - Risk management plan

English (EN) (1.33 MB - PDF)

**First published:** 04/05/2021

**Last updated:** 29/01/2024

[View](/en/documents/rmp/evrysdi-epar-risk-management-plan_en.pdf)

## Product information

Evrysdi : EPAR - Product information

English (EN) (775.78 KB - PDF)

**First published:** 04/05/2021

**Last updated:** 20/01/2026

[View](/en/documents/product-information/evrysdi-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-358)

български (BG) (1.72 MB - PDF)

**First published:**

04/05/2021

**Last updated:**

20/01/2026

[View](/bg/documents/product-information/evrysdi-epar-product-information_bg.pdf)

español (ES) (1.62 MB - PDF)

**First published:**

04/05/2021

**Last updated:**

20/01/2026

[View](/es/documents/product-information/evrysdi-epar-product-information_es.pdf)

čeština (CS) (1.64 MB - PDF)

**First published:**

04/05/2021

**Last updated:**

20/01/2026

[View](/cs/documents/product-information/evrysdi-epar-product-information_cs.pdf)

dansk (DA) (1.52 MB - PDF)

**First published:**

04/05/2021

**Last updated:**

20/01/2026

[View](/da/documents/product-information/evrysdi-epar-product-information_da.pdf)

Deutsch (DE) (1.93 MB - PDF)

**First published:**

04/05/2021

**Last updated:**

20/01/2026

[View](/de/documents/product-information/evrysdi-epar-product-information_de.pdf)

eesti keel (ET) (1.55 MB - PDF)

**First published:**

04/05/2021

**Last updated:**

20/01/2026

[View](/et/documents/product-information/evrysdi-epar-product-information_et.pdf)

ελληνικά (EL) (2.11 MB - PDF)

**First published:**

04/05/2021

**Last updated:**

20/01/2026

[View](/el/documents/product-information/evrysdi-epar-product-information_el.pdf)

français (FR) (1.58 MB - PDF)

**First published:**

04/05/2021

**Last updated:**

20/01/2026

[View](/fr/documents/product-information/evrysdi-epar-product-information_fr.pdf)

hrvatski (HR) (1.92 MB - PDF)

**First published:**

04/05/2021

**Last updated:**

20/01/2026

[View](/hr/documents/product-information/evrysdi-epar-product-information_hr.pdf)

íslenska (IS) (1.56 MB - PDF)

**First published:**

04/05/2021

**Last updated:**

20/01/2026

[View](/is/documents/product-information/evrysdi-epar-product-information_is.pdf)

italiano (IT) (1.47 MB - PDF)

**First published:**

04/05/2021

**Last updated:**

20/01/2026

[View](/it/documents/product-information/evrysdi-epar-product-information_it.pdf)

latviešu valoda (LV) (1.44 MB - PDF)

**First published:**

04/05/2021

**Last updated:**

20/01/2026

[View](/lv/documents/product-information/evrysdi-epar-product-information_lv.pdf)

lietuvių kalba (LT) (1.81 MB - PDF)

**First published:**

04/05/2021

**Last updated:**

20/01/2026

[View](/lt/documents/product-information/evrysdi-epar-product-information_lt.pdf)

magyar (HU) (1.58 MB - PDF)

**First published:**

04/05/2021

**Last updated:**

20/01/2026

[View](/hu/documents/product-information/evrysdi-epar-product-information_hu.pdf)

Malti (MT) (1.8 MB - PDF)

**First published:**

04/05/2021

**Last updated:**

20/01/2026

[View](/mt/documents/product-information/evrysdi-epar-product-information_mt.pdf)

Nederlands (NL) (1.6 MB - PDF)

**First published:**

04/05/2021

**Last updated:**

20/01/2026

[View](/nl/documents/product-information/evrysdi-epar-product-information_nl.pdf)

norsk (NO) (1.59 MB - PDF)

**First published:**

04/05/2021

**Last updated:**

20/01/2026

[View](/no/documents/product-information/evrysdi-epar-product-information_no.pdf)

polski (PL) (1.55 MB - PDF)

**First published:**

04/05/2021

**Last updated:**

20/01/2026

[View](/pl/documents/product-information/evrysdi-epar-product-information_pl.pdf)

português (PT) (1.62 MB - PDF)

**First published:**

04/05/2021

**Last updated:**

20/01/2026

[View](/pt/documents/product-information/evrysdi-epar-product-information_pt.pdf)

română (RO) (1.72 MB - PDF)

**First published:**

04/05/2021

**Last updated:**

20/01/2026

[View](/ro/documents/product-information/evrysdi-epar-product-information_ro.pdf)

slovenčina (SK) (1.58 MB - PDF)

**First published:**

04/05/2021

**Last updated:**

20/01/2026

[View](/sk/documents/product-information/evrysdi-epar-product-information_sk.pdf)

slovenščina (SL) (1.55 MB - PDF)

**First published:**

04/05/2021

**Last updated:**

20/01/2026

[View](/sl/documents/product-information/evrysdi-epar-product-information_sl.pdf)

Suomi (FI) (1.43 MB - PDF)

**First published:**

04/05/2021

**Last updated:**

20/01/2026

[View](/fi/documents/product-information/evrysdi-epar-product-information_fi.pdf)

svenska (SV) (1.64 MB - PDF)

**First published:**

04/05/2021

**Last updated:**

20/01/2026

[View](/sv/documents/product-information/evrysdi-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** R/0000275338 08/01/2026

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Evrysdi : EPAR - All authorised presentations

English (EN) (14.15 KB - PDF)

**First published:** 04/05/2021

**Last updated:** 14/07/2025

[View](/en/documents/all-authorised-presentations/evrysdi-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-810)

български (BG) (45.51 KB - PDF)

**First published:**

04/05/2021

**Last updated:**

14/07/2025

[View](/bg/documents/all-authorised-presentations/evrysdi-epar-all-authorised-presentations_bg.pdf)

español (ES) (15 KB - PDF)

**First published:**

04/05/2021

**Last updated:**

14/07/2025

[View](/es/documents/all-authorised-presentations/evrysdi-epar-all-authorised-presentations_es.pdf)

čeština (CS) (35.88 KB - PDF)

**First published:**

04/05/2021

**Last updated:**

14/07/2025

[View](/cs/documents/all-authorised-presentations/evrysdi-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (16.99 KB - PDF)

**First published:**

04/05/2021

**Last updated:**

14/07/2025

[View](/da/documents/all-authorised-presentations/evrysdi-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (13.55 KB - PDF)

**First published:**

04/05/2021

**Last updated:**

14/07/2025

[View](/de/documents/all-authorised-presentations/evrysdi-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (13.37 KB - PDF)

**First published:**

04/05/2021

**Last updated:**

14/07/2025

[View](/et/documents/all-authorised-presentations/evrysdi-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (41.32 KB - PDF)

**First published:**

04/05/2021

**Last updated:**

14/07/2025

[View](/el/documents/all-authorised-presentations/evrysdi-epar-all-authorised-presentations_el.pdf)

français (FR) (13.21 KB - PDF)

**First published:**

04/05/2021

**Last updated:**

14/07/2025

[View](/fr/documents/all-authorised-presentations/evrysdi-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (34.06 KB - PDF)

**First published:**

04/05/2021

**Last updated:**

14/07/2025

[View](/hr/documents/all-authorised-presentations/evrysdi-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (13.32 KB - PDF)

**First published:**

04/05/2021

**Last updated:**

14/07/2025

[View](/is/documents/all-authorised-presentations/evrysdi-epar-all-authorised-presentations_is.pdf)

italiano (IT) (18.16 KB - PDF)

**First published:**

04/05/2021

**Last updated:**

14/07/2025

[View](/it/documents/all-authorised-presentations/evrysdi-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (36.92 KB - PDF)

**First published:**

04/05/2021

**Last updated:**

14/07/2025

[View](/lv/documents/all-authorised-presentations/evrysdi-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (36.03 KB - PDF)

**First published:**

04/05/2021

**Last updated:**

14/07/2025

[View](/lt/documents/all-authorised-presentations/evrysdi-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (36.87 KB - PDF)

**First published:**

04/05/2021

**Last updated:**

14/07/2025

[View](/hu/documents/all-authorised-presentations/evrysdi-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (41.45 KB - PDF)

**First published:**

04/05/2021

**Last updated:**

14/07/2025

[View](/mt/documents/all-authorised-presentations/evrysdi-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (13.26 KB - PDF)

**First published:**

04/05/2021

**Last updated:**

14/07/2025

[View](/nl/documents/all-authorised-presentations/evrysdi-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (16.99 KB - PDF)

**First published:**

04/05/2021

**Last updated:**

14/07/2025

[View](/no/documents/all-authorised-presentations/evrysdi-epar-all-authorised-presentations_no.pdf)

polski (PL) (39.68 KB - PDF)

**First published:**

04/05/2021

**Last updated:**

14/07/2025

[View](/pl/documents/all-authorised-presentations/evrysdi-epar-all-authorised-presentations_pl.pdf)

português (PT) (14.22 KB - PDF)

**First published:**

04/05/2021

**Last updated:**

14/07/2025

[View](/pt/documents/all-authorised-presentations/evrysdi-epar-all-authorised-presentations_pt.pdf)

română (RO) (37.02 KB - PDF)

**First published:**

04/05/2021

**Last updated:**

14/07/2025

[View](/ro/documents/all-authorised-presentations/evrysdi-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (34.35 KB - PDF)

**First published:**

04/05/2021

**Last updated:**

14/07/2025

[View](/sk/documents/all-authorised-presentations/evrysdi-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (30.03 KB - PDF)

**First published:**

04/05/2021

**Last updated:**

14/07/2025

[View](/sl/documents/all-authorised-presentations/evrysdi-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (13.4 KB - PDF)

**First published:**

04/05/2021

**Last updated:**

14/07/2025

[View](/fi/documents/all-authorised-presentations/evrysdi-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (19.96 KB - PDF)

**First published:**

04/05/2021

**Last updated:**

14/07/2025

[View](/sv/documents/all-authorised-presentations/evrysdi-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Evrysdi Active substance risdiplam International non-proprietary name (INN) or common name risdiplam Therapeutic area (MeSH) Muscular Atrophy, Spinal Anatomical therapeutic chemical (ATC) code M09AX10

### Pharmacotherapeutic group

Other drugs for disorders of the musculo-skeletal system

### Therapeutic indication

Evrysdi is indicated for the treatment of 5q spinal muscular atrophy (SMA) in patients with a clinical diagnosis of SMA Type 1, Type 2 or Type 3 or with one to four SMN2 copies.

## Authorisation details

EMA product number EMEA/H/C/005145

Accelerated assessment

This medicine had an accelerated assessment. This means that it is a medicine of major interest for public health, so its timeframe for review was 150 evaluation days rather than 210. For more information, see [Accelerated assessment](/node/69621) .

Additional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under [additional monitoring](/node/68821) .

PRIME: priority medicine

This medicine was granted entry to the EMA Priority Medicines (PRIME) scheme during its development. PRIME is a scheme launched by EMA to enhance support for the development of medicines that target an unmet medical need. This voluntary scheme is based on enhanced interaction and early dialogue with developers of promising medicines, to optimise development plans and speed up evaluation so these medicines can reach patients earlier. For more information, see [PRIME: priority medicines](/node/69853) .

Marketing authorisation holder

Roche Registration GmbH

Emil-Barell-Strasse 1 79639 Grenzach-Wyhlen Germany

Opinion adopted 25/02/2021 Marketing authorisation issued 26/03/2021 Revision 13

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Evrysdi : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (133.34 KB - PDF)

**First published:** 14/07/2025

**Last updated:** 20/01/2026

[View](/en/documents/procedural-steps-after/evrysdi-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Evrysdi : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (188.48 KB - PDF)

**First published:** 19/01/2022

**Last updated:** 14/07/2025

[View](/en/documents/procedural-steps-after/evrysdi-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

Evrysdi-H-C-005145-X-0024-G : EPAR - Assessment report - Variation

Adopted

Reference Number: EMA/130688/2025

English (EN) (494.01 KB - PDF)

**First published:** 14/07/2025

[View](/en/documents/variation-report/evrysdi-h-c-005145-x-0024-g-epar-assessment-report-variation_en.pdf)

Evrysdi-H-C-005145-II-0027 : EPAR - Assessment report - Variation

Reference Number: EMA/CHMP/321325/2024

English (EN) (2.5 MB - PDF)

**First published:** 02/10/2024

[View](/en/documents/variation-report/evrysdi-h-c-005145-ii-0027-epar-assessment-report-variation_en.pdf)

Evrysdi-H-C-005145-II-0022 : EPAR - Assessment report - Variation

Adopted

Reference Number: EMA/412864/2024

English (EN) (1.62 MB - PDF)

**First published:** 12/09/2024

[View](/en/documents/variation-report/evrysdi-h-c-005145-ii-0022-epar-assessment-report-variation_en.pdf)

Evrysdi-H-C-005145-II-0005-G : EPAR - Assessment report - variation

Adopted

Reference Number: EMA/CHMP/391797/2023

English (EN) (3.8 MB - PDF)

**First published:** 22/09/2023

[View](/en/documents/variation-report/evrysdi-h-c-005145-ii-0005-g-epar-assessment-report-variation_en.pdf)

CHMP post-authorisation summary of positive opinion for Evrysdi

Adopted

Reference Number: EMA/CHMP/807714/2022

English (EN) (143.08 KB - PDF)

**First published:** 21/07/2023

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-evrysdi_en.pdf)

## Initial marketing authorisation documents

Evrysdi : Orphan maintenance assessment report (initial authorisation)

Adopted

Reference Number: EMA/OD/0000039037

English (EN) (513.15 KB - PDF)

**First published:** 04/05/2021

**Last updated:** 12/09/2023

[View](/en/documents/orphan-maintenance-report/evrysdi-orphan-maintenance-assessment-report-initial-authorisation_en.pdf)

Evrysdi : EPAR - Public assessment report

Adopted

Reference Number: EMA/216061/2021

English (EN) (8.87 MB - PDF)

**First published:** 04/05/2021

[View](/en/documents/assessment-report/evrysdi-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Evrysdi

Adopted

Reference Number: EMA/CHMP/19316/2021

English (EN) (129.37 KB - PDF)

**First published:** 26/02/2021

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-evrysdi_en.pdf)

#### News on Evrysdi

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 17-20 July 2023](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-17-20-july-2023) 21/07/2023

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 February 2021](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-february-2021) 26/02/2021

[First oral treatment for spinal muscular atrophy (SMA) recommended for approval](/en/news/first-oral-treatment-spinal-muscular-atrophy-sma-recommended-approval) 26/02/2021

#### Product information - with tracked changes

The approved product information for this medicine is available below showing the changes since the previous procedure affecting the product information. The same document without tracked changes is above under 'Product information'.

Evrysdi : EPAR - Product information - tracked changes

English (EN) (1.38 MB - DOCX)

**First published:** 20/01/2026

[View](/en/documents/product-information-tracked-changes/evrysdi-epar-product-information-tracked-changes_en.docx)

[Other languages (24)](#file-language-dropdown-88)

български (BG) (1.41 MB - DOCX)

**First published:**

20/01/2026

[View](/bg/documents/product-information-tracked-changes/evrysdi-epar-product-information-tracked-changes_bg.docx)

español (ES) (1.5 MB - DOCX)

**First published:**

20/01/2026

[View](/es/documents/product-information-tracked-changes/evrysdi-epar-product-information-tracked-changes_es.docx)

čeština (CS) (1.3 MB - DOCX)

**First published:**

20/01/2026

[View](/cs/documents/product-information-tracked-changes/evrysdi-epar-product-information-tracked-changes_cs.docx)

dansk (DA) (1.38 MB - DOCX)

**First published:**

20/01/2026

[View](/da/documents/product-information-tracked-changes/evrysdi-epar-product-information-tracked-changes_da.docx)

Deutsch (DE) (3.25 MB - DOCX)

**First published:**

20/01/2026

[View](/de/documents/product-information-tracked-changes/evrysdi-epar-product-information-tracked-changes_de.docx)

eesti keel (ET) (1.32 MB - DOCX)

**First published:**

20/01/2026

[View](/et/documents/product-information-tracked-changes/evrysdi-epar-product-information-tracked-changes_et.docx)

ελληνικά (EL) (1.43 MB - DOCX)

**First published:**

20/01/2026

[View](/el/documents/product-information-tracked-changes/evrysdi-epar-product-information-tracked-changes_el.docx)

français (FR) (1.8 MB - DOCX)

**First published:**

20/01/2026

[View](/fr/documents/product-information-tracked-changes/evrysdi-epar-product-information-tracked-changes_fr.docx)

hrvatski (HR) (1.67 MB - DOCX)

**First published:**

20/01/2026

[View](/hr/documents/product-information-tracked-changes/evrysdi-epar-product-information-tracked-changes_hr.docx)

íslenska (IS) (1.42 MB - DOCX)

**First published:**

20/01/2026

[View](/is/documents/product-information-tracked-changes/evrysdi-epar-product-information-tracked-changes_is.docx)

italiano (IT) (1.32 MB - DOCX)

**First published:**

20/01/2026

[View](/it/documents/product-information-tracked-changes/evrysdi-epar-product-information-tracked-changes_it.docx)

latviešu valoda (LV) (1.46 MB - DOCX)

**First published:**

20/01/2026

[View](/lv/documents/product-information-tracked-changes/evrysdi-epar-product-information-tracked-changes_lv.docx)

lietuvių kalba (LT) (1.4 MB - DOCX)

**First published:**

20/01/2026

[View](/lt/documents/product-information-tracked-changes/evrysdi-epar-product-information-tracked-changes_lt.docx)

magyar (HU) (1.41 MB - DOCX)

**First published:**

20/01/2026

[View](/hu/documents/product-information-tracked-changes/evrysdi-epar-product-information-tracked-changes_hu.docx)

Malti (MT) (1.3 MB - DOCX)

**First published:**

20/01/2026

[View](/mt/documents/product-information-tracked-changes/evrysdi-epar-product-information-tracked-changes_mt.docx)

Nederlands (NL) (1.5 MB - DOCX)

**First published:**

20/01/2026

[View](/nl/documents/product-information-tracked-changes/evrysdi-epar-product-information-tracked-changes_nl.docx)

norsk (NO) (1.43 MB - DOCX)

**First published:**

20/01/2026

[View](/no/documents/product-information-tracked-changes/evrysdi-epar-product-information-tracked-changes_no.docx)

polski (PL) (1.5 MB - DOCX)

**First published:**

20/01/2026

[View](/pl/documents/product-information-tracked-changes/evrysdi-epar-product-information-tracked-changes_pl.docx)

português (PT) (1.56 MB - DOCX)

**First published:**

20/01/2026

[View](/pt/documents/product-information-tracked-changes/evrysdi-epar-product-information-tracked-changes_pt.docx)

română (RO) (1.51 MB - DOCX)

**First published:**

20/01/2026

[View](/ro/documents/product-information-tracked-changes/evrysdi-epar-product-information-tracked-changes_ro.docx)

slovenčina (SK) (1.4 MB - DOCX)

**First published:**

20/01/2026

[View](/sk/documents/product-information-tracked-changes/evrysdi-epar-product-information-tracked-changes_sk.docx)

slovenščina (SL) (1.45 MB - DOCX)

**First published:**

20/01/2026

[View](/sl/documents/product-information-tracked-changes/evrysdi-epar-product-information-tracked-changes_sl.docx)

Suomi (FI) (1.29 MB - DOCX)

**First published:**

20/01/2026

[View](/fi/documents/product-information-tracked-changes/evrysdi-epar-product-information-tracked-changes_fi.docx)

svenska (SV) (1.3 MB - DOCX)

**First published:**

20/01/2026

[View](/sv/documents/product-information-tracked-changes/evrysdi-epar-product-information-tracked-changes_sv.docx)

#### More information on Evrysdi

This product is no longer an orphan medicine. It was originally [designated an orphan medicine](/en/medicines/human/orphan-designations/eu-3-19-2145) on 26 February 2019. Evrysdi was withdrawn from the Community register of orphan medicinal products in September 2023 upon request of the marketing authorisation holder.

#### More information on Evrysdi

- [EMEA-002070-PIP01-16-M07 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-002070-pip01-16-m07)
- [Evrysdi - direct healthcare professional communication (DHPC)](/en/medicines/dhpc/evrysdi)
- [Risdiplam Single-Arm Pregnancy Safety Study - post-authorisation study](https://catalogues.ema.europa.eu/study/49676)

**This page was last updated on** 20/01/2026

## Share this page

[Back to top](#main-content)